---
title: "\"Performance\" ETHK LABS INC. last year net profit was 34.93 million RMB, down 86.6%, no dividend declared"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280934840.md"
description: "ETHK LABS INC. announced its full-year results for the year ended December last year, with a revenue of RMB 2.821 billion, a year-on-year decrease of 10.8%. The net profit was RMB 34.933 million, a year-on-year decrease of 86.6%; earnings per share were 2.16 cents. No dividend was declared"
datetime: "2026-03-30T01:12:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280934840.md)
  - [en](https://longbridge.com/en/news/280934840.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280934840.md)
---

# "Performance" ETHK LABS INC. last year net profit was 34.93 million RMB, down 86.6%, no dividend declared

ETHK LABS INC. (01931.HK) announced its full-year results for the year ended last December, with a revenue of RMB 2.821 billion, a year-on-year decrease of 10.8%. The net profit was RMB 34.933 million, a year-on-year decrease of 86.6%; earnings per share were 2.16 cents. No dividend was declared

### Related Stocks

- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [01931.HK](https://longbridge.com/en/quote/01931.HK.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [512170.CN](https://longbridge.com/en/quote/512170.CN.md)

## Related News & Research

- [JD Health files HKEX return disclosing share buyback at HKD 40.3 each](https://longbridge.com/en/news/287057883.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Upsher-Smith launches Restasis generic cyclosporine ophthalmic emulsion 0.05%](https://longbridge.com/en/news/287079790.md)